Healthcare News | BioTuesdays by Kilmer Lucas IR

Markets

Janney starts Abcam at buy; fair value estimate £17

Janney Montgomery Scott initiated coverage of Abcam plc (LSE:ABC) with a “buy” rating and fair value estimate of £17. The stock closed at £14.72 on July 1.

July 2, 2019

Markets

Dawson James starts Adamis Pharma at buy; PT $5

Dawson James launched coverage of Adamis Pharmaceuticals (NASDAQ:ADMP) with a “buy” rating and $5 price target. The stock closed at $1.30 on July 1.

July 2, 2019

Markets

HCW starts Principia Biopharma at buy; PT $55

H.C. Wainwright initiated coverage of Principia Biopharma (NASDAQ:PRNB) with a “buy” rating and $55 price target. The stock closed at $37.61, up $4.42, on July 1.

July 2, 2019

Markets

Dawson James starts IsoRay at buy; PT $1

Dawson James Securities initiated coverage of IsoRay (NYSE American:ISR) with a “buy” rating and $1 price target. The stock closed at 41 cents on July 1.

July 1, 2019

Markets

Roth starts Fortress Biotech at buy; PT $4

Roth Capital Partners launched coverage of Fortress Biotech (NASDAQ:FBIO), which acquires and develops biopharmaceutical assets, with a “buy” rating and price target of $4. The stock closed at $1.55 on July 1.

July 1, 2019

Developments

vTv Therapeutics starts Phase 2 trial in patients with AD and T2D

vTv Therapeutics (NASDAQ:VTVT) initiated a Phase 2 trial of azeliragon in patients with Alzheimer’s disease (AD) and Type 2 diabetes (T2D).

June 29, 2019

Developments

Arcturus Therapeutics gets FDA orphan drug designation for ARCT-810

Arcturus Therapeutics (NASDAQ:ARCT) received FDA orphan drug designation for ARCT-810 for the treatment of ornithine transcarbamylase (OTC) deficiency.

June 29, 2019

Markets

Roth starts Merus at buy; PT $20

Roth Capital Partners launched coverage of Netherlands-based Merus NV (NASDAQ:MRUS) with a “buy” rating and $20 price target. The stock closed at $14.12 on June 27.

June 28, 2019

Developments

Zogenix reaches agreement with FDA for FINTEPLA NDA resubmission

Following a Type A meeting with the FDA, Zogenix (NASDAQ:ZGNX) reported that it plans to resubmit its NDA for FINTEPLA for the treatment of seizures associated with Dravet syndrome.

June 27, 2019

Developments

Dova Pharma gets FDA sNDA approval for thrombocytopenia drug

Dova Pharmaceuticals (NASDAQ:DOVA) reported that the FDA approved DOPTELET’s supplemental NDA, expanding its use to include the treatment of adults with chronic immune thrombocytopenia (ITP) who have not responded to...

June 27, 2019

Developments

Aridis Pharma gets orphan drug designation for CF drug

Aridis Pharmaceuticals (NASDAQ:ARDS) received FDA orphan drug designation for AR-501 for the treatment of lung infections in patients with cystic fibrosis (CF).

June 27, 2019

Developments

Novavax confirms accelerated approval pathway for NanoFlu

Novavax (NASDAQ:NVAX) reported that the FDA recently made the accelerated approval pathway available for NanoFlu, and that Novavax will be pursuing that pathway for licensure of the vaccine.

June 27, 2019

Janney starts Abcam at buy; fair value estimate £17

Dawson James starts Adamis Pharma at buy; PT $5

HCW starts Principia Biopharma at buy; PT $55

Dawson James starts IsoRay at buy; PT $1

Roth starts Fortress Biotech at buy; PT $4

vTv Therapeutics starts Phase 2 trial in patients with AD and T2D

Arcturus Therapeutics gets FDA orphan drug designation for ARCT-810

Roth starts Merus at buy; PT $20

Zogenix reaches agreement with FDA for FINTEPLA NDA resubmission

Dova Pharma gets FDA sNDA approval for thrombocytopenia drug

Aridis Pharma gets orphan drug designation for CF drug

Novavax confirms accelerated approval pathway for NanoFlu

General

More